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Zusammenfassung 
 “Peptidmimics” von konformationellen Epitopen eines Tumorantigens werden auch 
als Mimotope bezeichnet und stellen vielversprechende Kandidaten für die Entwicklung 
von Tumorvakzinen dar. Derartige Mimotopvakzine induzieren eine Tumorantigen-
spezifische Immunantwort. Kürzlich konnte für das maligne Melanom gezeigt werden, 
dass durch Vakzinierung von Kaninchen mit einem an Tetanustoxoid gekoppelten 
Mimotop des HMW-MAA (“high molecular weight-melanoma associated antigen”) 
Antikörper gebildet wurden, die das Tumorwachstum in einem Melanommausmodell 
hemmen konnten. HMW-MAA wurde als Zielantigen gewählt, da es von vielen 
Melanomzellen exprimiert wird und in normalen Geweben fast nicht vorkommt. 
 Das Ziel dieser Dissertation war die Entwicklung einer Polymimotopvakzine, die 
eine starke humorale Immunantwort gegen mehrere Epitope des HMW-MAA 
induzieren sollte. Verschiedene Studien haben gezeigt, dass Vakzine, die gegen mehr 
als ein Epitop eines Tumorantigens gerichtet sind, eine höhere Erfolgsrate aufweisen. 
Der Effekt der induzierten Antikörper sollte sowohl in vitro (Tumorproliferation, 
antikörperabhängige, zellvermitteltete Zytotoxizität, komplementabhängige Zyto-
toxizität) als auch in vivo (Melanommausmodell: C57BL/6 Mäuse mit einem 
subkutanen Tumor der HMW-MAA transfizierten Mausmelanomzelllinie B16F10) 
untersucht werden. 
 Mittels einer linearen pIII-12mer Phagenpeptidbank wurden Peptidliganden für eine 
Reihe von anti-HMW-MAA monoklonalen Antikörpern (mAbs VT80.12, VF1-TP43, 
VF1-TP34, 149.53 und 225.28S F(ab')2) selektiert. Diese Antikörper erkennen 
unterschiedliche Epitope des HMW-MAA, weshalb sie sich gegenseitig in ihrer 
Bindung nicht inhibieren. Es wurden verschiedene Panningstrategien angewendet 
(Panning mit Oberflächenimmobilisierung und in Lösung mit Protein G- bzw. 
Streptavidin-Bindung). Für jeden mAb wurde mindestens ein Peptidligand identifiziert. 
Es waren aber nur die Peptide, die für die mAbs VT80.12 und VF1-TP43 identifiziert 
wurden, auch in der Lage, die Bindung der entsprechenden mAbs an das HMW-MAA 
zu inhibieren. Daher wurden diese beiden Peptide jeweils an KLH („keyhole limpet 
hemocyanin“) als immunogenen Träger gekoppelt. Die in Kaninchen induzierten 
Antikörper zeigten einen starken Hintergrund verursacht durch die anti-KLH 
Antikörper. Durch die Immunisierung von BALB/c Mäusen konnte dieses Problem 
gelöst werden. Beide Peptide induzierten Peptid-spezifische Antikörper, aber nur das 
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VT80.12-Peptid induzierte auch anti-HMW-MAA Antikörper. Diese Antikörper waren 
jedoch nicht in der Lage, das Wachstum der HMW-MAA exprimierenden humanen 
Melanomzelllinie 518A2 in vitro zu inhibieren. 
 In dieser Arbeit konnten sehr viele neue Informationen für die Selektion von 
Mimotopen gewonnen werden, jedoch konnten noch keine idealen Mimotopkandidaten 
für die Polymimotopvakzine identifiziert und im Melanommausmodell getestet werden. 
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Summary 
 Peptide mimics, also called mimotopes, of conformational epitopes of tumor antigens 
are promising candidates for the design of anti-tumor vaccines. Such mimotope 
vaccines stimulate a tumor antigen specific immune response. For melanoma, it was 
recently demonstrated that vaccination of rabbits with a mimotope of the high molecular 
weight-melanoma associated antigen (HMW-MAA) coupled to tetanus toxoid induced 
antibodies that suppressed tumor growth in a melanoma xenotransplant severe 
combined immunodeficiency mouse model. The HMW-MAA was selected as target 
antigen because it is highly expressed on melanoma cells and has a restricted 
distribution in normal tissues. 
 The aim of this thesis was to develop a polymimotope vaccine that would induce a 
strong humoral immune response against several epitopes of the HMW-MAA. Several 
studies have demonstrated that vaccines directed against multiple epitopes of a tumor 
antigen have a higher success rate. The effect of the induced antibodies were then to be 
tested in vitro (tumor proliferation, antibody-dependent cell-mediated cytotoxicity, 
complement-dependent cytotoxicity) and in vivo (melanoma mouse model: C57BL/6 
mice harboring a subcutaneous tumor of the mouse melanoma cell line B16F10 
transfected with the HMW-MAA). 
 Peptide ligands for a panel of anti-HMW-MAA monoclonal antibodies (mAbs)  
– VT80.12, VF1-TP43, VF1-TP34, 149.53, and 225.28S F(ab')2 – which recognize 
distinct epitopes on the HMW-MAA and do not cross-inhibit each other were selected 
using a linear pIII-12mer phage display peptide library by surface panning as well as 
solution-phase panning with protein G or streptavidin capture. Peptide ligands were 
identified for each mAb, but only one peptide identified for each of the mAbs VT80.12 
and VF1-TP43 was able to inhibit the binding of the respective mAb to the HMW-
MAA. These two peptides were then coupled to keyhole limpet hemocyanin (KLH) as 
immunogenic carrier and used for immunization of rabbits. Due to the high background 
of the KLH-induced antibodies, further immunizations were performed in BALB/c 
mice. Both peptides induced a peptide specific immune response but only the VT80.12-
peptide induced anti-HMW-MAA antibodies. However, these antibodies did not 
suppress the proliferation of the HMW-MAA expressing human melanoma cell line 
518A2 in vitro. 
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 In summary, we have produced a lot of new methodologic know-how on the 
selection of mimotopes but could not yet identify ideal mimotope candidates which 
could be tested as parts of a polymimotope vaccine in the melanoma mouse model. 
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Malignant melanoma 
 
Malignant melanoma represents the most common form of fatal skin cancer and one of 
the most common fatal malignancies among young adults. Worldwide incidence rates 
have been constantly increasing for at least 30 years more than that of any other cancer, 
resulting in an estimated increase at a rate of 5% per year [1-4]. In 2009, the American 
Cancer Society estimated 68,720 new cases and 8,650 deaths for melanoma in the USA 
[5]. As shown in figure 1, invasive melanoma currently is the fifth most frequently 
diagnosed cancer in men and the sixth most frequently diagnosed cancer in women in 
the USA [5,6]. 
 
 
Figure 1. Estimated new melanoma cases are indicated for men and women with black 
arrows (adapted from Cancer Facts & Figures 2009 [5]) 
 
The highest incidence of melanoma worldwide is observed in Australia – with a clear 
latitude gradient within the continent – and in New Zealand (Table 1). Reported 
incidence rates are much lower for the USA and Europe. All European countries report 
a higher incidence in females than males. In contrast, higher incidence for males is 
reported in Australia, New Zealand, and the USA [4]. In addition, the American Cancer 
Society reports rapid increases among young white women (3.8% annual increase since 
1995 in those aged 15-34 years) and older white men (8.8% annual increase since 2003 
in those ≥65 years) [5]. 
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Table 1. Comparative melanoma incidence for selected states and countries worldwide 
for the time period 1998-2002 (adapted from MacKie et al. [4]) 
Incidence (per 105 subjects) Country 
Male Female 
Australia   
 Queensland 55.8 41.1 
 New South Wales 38.5 26.5 
 Victoria 27.3 23.4 
New Zealand 34.8 31.4 
US SEER 14 registries 19.4 14.4 
Switzerland, Vaud 16.6 19.6 
Norway 14.2 14.6 
Sweden 11.9 12.1 
Denmark 11.9 14.1 
Latvia 3.2 4.2 
Lithuania 3.7 5.2 
Estonia 5.3 6.6 
Belarus 2.7 3.5 
Serbia 3.8 4.8 
 
Although diagnosis of melanoma has significantly improved [7], leading to an increase 
in the percentage of patients being diagnosed with “thin” melanomas (≤1 mm) and a 
decrease in the percentage of patients diagnosed with “thick” melanomas (>4 mm) [8], 
the mortality rate for melanoma has been continually increasing over the past decade 
[1,4]. 
 
Melanomas generally originate from benign nevi, which are clonally expanded 
melanocytes that proliferate abnormally but do not progress [9]. The overcoming of 
senescence leads to a dysplastic nevus, which can progress to a stage of spreading with 
low invasive potential (radial growth phase). The next stage (vertical growth phase) 
often results in metastases to local lymph nodes and eventually to distant sites, 
including other skin sites, pleura, lungs, liver and brain [9]. A schematic view of this 
process is shown in figure 2. 
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Figure 2. Melanoma development and metastasis (from Miller AJ and Mihm MC [10]) 
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Melanoma associated antigens (MAAs) 
 
Tumor associated antigens or tumor antigens are antigens that are associated with a 
certain tumor. Thus, melanoma associated antigens (MAAs) or melanoma antigens are 
highly expressed on melanoma cells. Several MAAs have been identified and 
characterized. They are grouped into different categories as shown in table 2 and can be 
expressed at different melanoma stages, i.e. primary or metastatic melanomas [11]. The 
identification and structural characterization of MAAs opened the possibility to 
specifically target certain MAAs with immunotherapeutic approaches, as described in 
following sections. 
 
Table 2. Human melanoma antigens (adapted from Hodi FS [11]) 
Melanocyte lineage/differentiation antigens (abundant proteins in melanin production) 
e.g. Tyrosinase, gp75 (tyrosinase related protein-1, TRP-1), gp100, MelanA/MART-1, TRP-2 
 
Oncofetal/cancer-testis antigens (normally expressed in testis and placenta) 
e.g. MAGE family, BAGE family, GAGE family, NY-ESO-1 
 
Tumor-specific antigens (subtle mutations of normal cellular proteins) 
e.g. CDK4, β-catenin 
 
Other mutated peptides (activated as a result of cellular transformation) 
e.g. Mutated introns, N-acetylglucosaminyltransferase V gene product, MUM-1, p15 
 
Antigens indentified by monoclonal antibodies 
e.g. Gangliosides (GM2, GD2, GM3, and GD3), HMW-MAA, p97 melanotransferrin 
 
SEREX antigens 
e.g. D-1, SSX-2 
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High molecular weight-melanoma associated antigen (HMW-MAA) 
 
One of the MAAs is the high molecular weight-melanoma associated antigen (HMW-
MAA), also known as the chondroitin sulfate proteoglycan 4 (CSPG4) or melanoma 
chondroitin sulfate proteoglycan (MCSP). This MAA was originally identified with 
murine monoclonal antibodies (mAbs) on the surface of human melanoma cells at the 
beginning of the 1980’s [12,13]. 
 
The HMW-MAA gene is located on human chromosome 15 [14] and encodes a 2322 
amino acid (aa) long protein (UniProt accession number: Q6UVK1). A schematic view 
of the HMW-MAA sequence is shown in figure 3. The first 29 aa residues display a 
signal peptide and the remaining aa the core protein which contains three major domain 
structures: a large extracellular domain (1), a short hydrophobic transmembrane region 
(2), and a short cytoplasmic tail (3). There are 15 potential N-linked glycosylation sites 
throughout the extracellular domain [1]. 
The expression of HMW-MAA seems to be regulated by a classical 5’ CpG island 
promoter that precedes the ten exons comprising the human HMW-MAA gene [15]. 
The level of methylation of the promoter predicts HMW-MAA expression in vivo. 
Unmethylated promoter DNA leads to HMW-MAA expression in human melanoma 
cells, whereas methylation of promoter DNA results in the absence of HMW-MAA 
expression in normal human lymphocytes [15]. 
 
 
Figure 3. Analysis of the full-length aa sequence of the HMW-MAA protein (from 
Campoli et al. [1]) 
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Potential HMW-MAA homologues have been identified in several animals, i.e. zebra 
fish, frog, mouse, rat, chicken, dog, cattle, horse, rhesus monkey, and chimpanzee [1]. 
With the exception of frog chondroitin sulfate proteoglycan, each of the animal 
homologues shares over 80% aa sequence identity with HMW-MAA and with each 
other. NG2, the rat homologue, and AN2, the mouse homologue, share more than 90% 
homology with HMW-MAA. 
 
HMW-MAA is a highly glycosylated integral membrane chondroitin sulfate proteo-
glycan consisting of an N-linked 280 kDa glycoprotein component and a 450 kDa 
chondroitin sulfate proteoglycan component expressed on the cell membrane [1,16]. 
The 280 kDa and 450 kDa components of HMW-MAA contain the same core protein 
and can be expressed independently. Furthermore, the components are posttrans-
lationally modified in the trans-Golgi network through glycosylation and sulfation of 
carbohydrate moieties. HMW-MAA can be expressed with or without covalently 
attached chondroitin sulfate glycosaminoglycan [1,17,18]. The number of molecules 
was determined to be approximately 5x106 per melanoma cell [19]. 
 
Several lines of evidence suggest that HMW-MAA plays important roles in cell 
proliferation, cell migration, invasion, and angiogenesis [1]. HMW-MAA expression 
correlates with the increase of the proliferative capacity of melanoma cells [20]. In 
addition, HMW-MAA interacts with extracelluar matrix (ECM) components and 
promotes cell adhesion and migration, thereby influencing their metastatic potential. 
Melanoma cells which express HMW-MAA following transfection with HMW-MAA 
cDNA display higher migratory ability than the parental cells which do not express 
HMW-MAA [1]. Furthermore, anti-HMW-MAA mAb inhibit melanoma cell 
attachment to capillary endothelium and interactions with various ECM components 
including collagen and collagen-fibronectin complexes [21] as well as cytoskeletal 
reorganization in migrating melanoma cells [1]. Garrigues et al. demonstrated that 
HMW-MAA expression is restricted to cell surface microspike domains of migrating 
cells in vitro [17]. As shown in Figure 4, both the co-localization of HMW-MAA and 
α4β1 integrin and the interactions between HMW-MAA and ECM components, such as 
laminin, tenascin, and types II, V, and VI collagen, lead to extensive microspike 
formation, cytoskeletal rearrangements, melanoma cell spreading and migration, as well 
as to the activation of focal adhesion kinase (FAK) and ERK 1/2 signaling cascades [1].
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Figure 4. Schematic view of HMW-MAA induced signal transduction (from Campoli 
et al. [1]) 
 
HMW-MAA is expressed at high levels on both activated pericytes and pericytes in 
angiogenic vasculature within the tumor environment as well as by angiogenic blood 
vessels in normally developing tissues and in neovasculature found in stroma and 
granulation tissue of healing wounds [1,22]. Therefore, it is suggested that HMW-MAA 
plays a role in the regulation of angiogensis. 
 
It was originally thought that HMW-MAA has a restricted distribution in normal 
tissues, having been initially detected only on melanocytes, endothelial cells, and 
pericytes [1,12,22]. More recently, it became evident that HMW-MAA has a broader 
distribution, being expressed by a number of normal and malignant cells. 
HMW-MAA is also expressed on restricted areas of the interfollicular epidermis as well 
as the basal layer of normal oral mucosa with the exception of foreskin and perineum, 
the basal layer of the outer root sheath and the follicular papilla of the hair follicle, 
chondrocytes, smooth muscle cells, angiomyolipomas, differentiated myofibers of the 
sarcolemma and neuromuscular junction of human postnatal skeletal muscle, microglial 
and mesangial cells of the renal glomerulus, and fetal epidermal melanocytes as well as 
in the vascular paracellular clefts of placental villi [1]. 
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HMW-MAA has been found to be expressed on more than 90% of surgically removed 
benign nevi and melanoma lesions, with a limited degree of intra- and interlesional 
heterogeneity [1]. HMW-MAA expression has also been found in astrocytomas, 
gliomas, neuroblastomas, squamous cell carcinoma of the head and neck, basal breast 
cancer, mesothelioma, pancreatic carcinoma, some types of renal cell carcinoma, 
chordoma, chondrosarcoma, soft tissue sarcomas, and hematologic malignancies 
(expression on blast cells in both childhood and adult acute lymphoblastic leukemia and 
childhood acute myeloid leukemia) as well as cancer stem cells [1]. 
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Therapy of melanoma 
 
While most early stage melanomas (thin primary tumors; stage 0-II) are highly curable 
with optimal surgical excision, patients with advanced stage melanoma (lymph node 
involvement and metastases; stage III-IV) have a poor prognosis and often succumb, 
due to failure of metastasis control [1,3,23-25]. 
Metastatic melanoma is highly resistant to conventional therapy, including standard 
chemotherapy and radiotherapy. The response rate for conventional agents, like 
cisplatin, dacarbazine or temozolomide, as single agent or in combination, is only 15-
25% [26-31]. Therefore, the need to develop and apply novel and improved therapeutic 
strategies for the treatment of melanoma has been emphasized. 
 
As melanoma is among the most immunogenic of all solid caners, a lot of different 
immunotherapeutic approaches to treat melanoma have been investigated in preclinical 
and clinical studies and have been the focus of several review articles in the recent past 
[3,9,25,26,32-38]. An overview describing the general mechanisms of the investigated 
strategies is shown in table 3. 
 
Table 3. Approaches for the treatment of melanoma (adapted from Nestle FO [34]) 
Active (= Vaccination) 
Whole cell vaccines (e.g. autologous or allogeneic melanoma cell lines)
Antigen-based vaccines (e.g. peptides, protein, DNA, RNA) 
Adjuvant-based vaccines (e.g. dendritic cells) 
 
Passive 
Adoptive cell transfer (e.g. tumor-infiltrating lymphocytes (TILs)) 
Antibodies (e.g. anti-CTLA-4) 
Inhibitors (targeting molecules in signal transduction pathways) 
Adjuvants (e.g. Toll-like receptor agonists) 
Cytokines (e.g. IL-2, IFN-α) 
 
So far, only the immune-modulating agents interferon-α (IFN-α) and interleukin-2 (IL-
2) are approved by the US Food and Drug Administration (FDA). IFN-α is administered 
for the treatment of high-risk melanoma patients. IL-2 is used for the treatment of 
patients with metastatic melanoma [25,32,33]. For both cytokines, the overall response 
rates remain low and the benefits must be balanced against several serious side-effects, 
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such as flu-like symptoms, anorexia, fatigue, depression, thyroid dysfunction, skin rash, 
altered blood cell counts, and liver toxicity [9,33]. 
 
Noteworthy, the development of a vaccine that would show significant clinical benefit 
in melanoma has not been successful by now, as clinical responses remain at a low rate. 
However, the extent of research activity in the field and a number of novel approaches 
indicate that such an approach remains attractive [36]. 
Encouraging results were obtained by using immunostimulatory mAbs directed to 
immune-receptor molecules to increase immune responses. MAbs of this type (e.g. anti-
CTLA-4, anti-CD137 and anti-CD40) are currently studied in clinical trials [25]. 
Nevertheless, complications such as autoimmunity and systemic inflammation are 
problematic side effects associated with these therapeutics. 
In addition, adoptive cell transfer of ex vivo expanded autologous tumor reactive 
lymphocytes in combination with lymphodepletion or myeloablation by the use of 
chemotherapy or radiochemotherapy resulted in 50-70% objective clinical response 
[39,40]. However, this are time-consuming and cost-intensive treatments, which are 
therefore at the moment not routinely applicable in the general clinical practice. 
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Monoclonal antibodies in clinical use 
 
As mentioned above, to date immunotherapeutic approaches to treat melanoma have not 
been successful. However, chimeric or humanized mAbs directed against tumor 
antigens of diverse malignancies represent a recent and very significant addition to the 
therapeutic anticancer armamentarium. Although considerations of side effects, therapy 
with mAbs is reasonably safe in comparison to other therapeutic modalities used for 
cancer patients. Today, several mAbs have been approved by the FDA as antibody-
based therapeutic anticancer drugs and are routinely used in the clinic. These antibodies 
are summarized in table 4. 
 
Table 4. FDA-approved tumor antigen specific mAbs for human cancers (adapted from 
Campoli et al. [41]) 
mAb Target Isotype FDA-approved disease 
Rituximab CD20 Chimeric IgG1 CD20+ low-grade lymphoma 
diffuse large B-cell lymphoma 
follicular lymphoma 
    
90Y Ibritumomab 
+ tiuxetan 
CD20 Radiolabeled murine IgG1 CD20+ low-grade lymphoma 
    
131I Tositumomab CD20 Radiolabeld murine IgG1 CD20+ low-grade lymphoma 
    
Alemtuzumab CD53 Humanized IgG1 Chronic lymphocytic leukemia 
    
Gemtuzumab 
+ ozogamicin 
CD33 Recombinant humanized IgG4 
-conjugated to calicheamicin 
Acute myelogenous leukemia 
    
Trastuzumab Her2/neu Humanized IgG1 Her2/neu+ breast cancer 
    
Cetuximab EGFR Chimeric IgG1 EGFR+ colon cancer 
    
Panitumumab EGFR Fully human IgG2 EGFR+ colon cancer 
    
Bevacizumab VEGF Humanized IgG1 Colon cancer 
recurrent or advanced non-small 
cell lung cancer 
metastatic breast cancer 
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The huge costs of the production of mAbs are the greatest disadvantage of this kind of 
therapy. Doses used in humans are typically in the mg per kg body weight range, and 
most regimens involve repetitive applications over longer time periods. Therefore, 
expensive GMP produced batches are required for quality control, toxicology and 
clinical trials. An example for the high costs is given in a recent publication where 
clinicians from the Norfolk and Norwich University Hospital estimated that more than  
€ 2.9 millions were necessary per year to make Herceptin® (Trastuzumab) available to 
75 patients who might be eligible for the treatment [42]. 
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Monoclonal antibodies directed to HMW-MAA 
 
Although poorly immunogenic in humans, the HMW-MAA is highly immunogenic in 
BALB/c mice, as indicated by the high frequency of HMW-MAA-specific antibody-
secreting hybridomas generated from BALB/c mice immunized with HMW-MAA-
bearing human melanoma cells [12]. Consequently, a large number of mouse anti-
HMW-MAA mAbs has been developed (see table 5). Analysis of a panel of mouse anti-
HMW-MAA mAb by cross-inhibition experiments classified them into at least six 
groups that identify distinct and spatially non-overlapping antigenic determinants [12]. 
In general, these anti-HMW-MAA mAbs are poor mediators of complement- and cell-
dependent cytotoxicity of melanoma cells, although they are able to inhibit spreading, 
migration and invasion of melanoma cells in vitro [1]. 
 
Table 5. Grouping of a panel of HMW-MAA-specific mAbs according to their epitope 
specificity (adapted from Campoli et al. [12]) 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
149.53 225.28S 763.74 VF1-TP34 VF1-TP41.2 VF20-VT87.41 
VZ68.2 VF4-ZP109 VT80.12 VF4-TP108 VF1-TP43 VF20-VT5-1 
 653.25 TP32 VF20-VT1.7  VF18.176 
   543  VT67.5 
   116  TP61.5 
     TP175-11 
     724 
     9.2.27 
 
It was demonstrated that two anti-HMW-MAA mAbs (225.28S and MK2-23) had anti-
tumor effects in vivo. The mAb 225.28S was generated by immunizing female BALB/c 
mice with human melanoma M21 cells [43]. An interesting effect was observed in a 
follow-up study of more than 300 patients who had received immunoscintigraphy with 
99mTc-labeled 225.28S F(ab')2 fragments as part of a routine melanoma staging protocol. 
Survival time was significantly longer in patients who had received multiple injections 
as compared to those who had received only a single dose [44]. This finding suggests 
that F(ab')2 fragments arrest tumor progression for a limited time and the effect cannot 
be due to any Fc mediated functions, as no Fc portions were present in the injected 
material. 
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Furthermore, Hafner et al. were able to demonstrate that the mAb 225.28S was able to 
suppress tumor growth in a human melanoma xenotransplant model in severe combined 
immunodeficiency (SCID) mice [45]. 
In addition, stage IV melanoma patients had a significant increase of survival 
prolongation upon immunization with the anti-idiotypic mAb MK2-23, which mimics 
the epitope of the anti-HMW-MAA mAb 763.74 [46,47]. 
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Cancer vaccines – from peptide to mimotope vaccines 
 
Passive administration with tumor antigen specific mAbs, like the treatment with the 
Herceptin® antibody, has produced promising results in the clinics. However, a number 
of concerns remains such as repeated treatments and associated costs, limited duration 
of therapeutic effectiveness, and possible undesired immunogenicity. Therefore, a 
therapeutic approach capable of inducing active specific immunity would offer 
sustained protection at a lower cost, preventive therapy and long term immunity. 
 
One of the great problems in developing cancer vaccines is that tumor associated self-
antigens do not induce an immune response, since the corresponding reactive B and T 
cell clones have been eliminated during the establishment of self-tolerance. Especially 
for melanoma, this kind of malignancy seems to be very efficient regarding tumor 
escape/evasion of the host immune responses via tumor-induced immunosuppression. 
The mechanisms of immunoediting include inhibition of maturation of antigen 
presenting cells or downregulation of MHC class I expression of melanoma cells. In 
addition, T cell tolerance or anergy is induced upon secretion of immunosuppressive 
cytokines like IL-10 and transforming growth factor-β (TGF-β) [33], as shown in Figure 
5. 
 
 
Figure 5. Overview of immunoediting (from Kirkwood et al. [33]) 
 
As most of the active melanoma vaccines aim to induce a cellular immune response by 
the induction of cytotoxic T lymphocytes [38], they somehow fail due the above 
mentioned immunoediting mechanisms used by melanoma. 
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Therefore, and since some tumor antigen specific mAbs are successfully used in the 
clinics to treat different cancers, several strategies have been developed to overcome 
this problem via focusing on B cells. As an example, research groups have predicted 
putative B cell epitopes of the tumor antigen Her-2/neu and could demonstrate that 
some of these B cell epitopes coupled to an immunogenic carrier protein induced a 
humoral immune response directed to the tumor antigen with anti-tumor activity 
[48,49]. 
 
Cancer vaccines designed to elicit an antibody response that targets antigenic sites on a 
tumor antigen must closely mimic the three-dimensional structure of the corresponding 
region on the antigen. Studies of the three-dimensional structures of antigen-antibody 
complexes showed that antigenic epitopes are conformational and vaccine design 
should consider such parameters to elicit antibodies of high affinity. 
Molecular mimicry provides a way to generate vaccine components that elicit and/or 
enhance an immune response against tumor antigens that are mostly non-mutated self-
antigens and therefore poorly or non immunogenic in patients. 
 
The benefits of synthetic peptides and the knowledge of the effects of epitope mimicry 
led to the development of mimotopes which are peptides that mimic the structure of the 
epitope of an antigen that is defined by an antibody. The term “mimotope” was 
introduced by Geysen and his colleagues in the 1980’s [50]. Easy identification of 
mimotopes was made feasible by the application of the so called “phage display” 
technology, which was developed by George P. Smith [51]. 
 
Mimotopes are selected using random peptide phage display libraries that consist of 
filamentous phage particles (e.g. bacteriophage M13, fd, and f1) displaying random 
peptides of defined length on their surface. Most commonly, peptides are either fused to 
the phage minor coat protein pIII (Gene 3 protein; Fig. 6) or, at a higher copy number, 
to the major coat protein pVIII (Gene 8 protein; Fig. 6). These are peptides from 4 to 40 
aa residues in length, assembled either in linear or in constrained (circular) form [52]. 
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Figure 6. Schematic illustration of the bacteriophage M13 (from Stopar et al. [53]) 
 
For biopanning, a mAb is immobilized and incubated with a phage display peptide 
library. Phages displaying specific peptides for the mAb bind to it and can then be 
eluted by lowering the pH. Amplification of the eluted phages occurs via infection of 
host cells, mostly E. coli. Amplified phages are then used for further rounds of infection 
to increase the number of specific phages. Single clones are then used to prepare DNA 
and to determine the sequences coding for the peptides. 
A peptide representing a mimotope has to fulfill two requirements: (1) it has to inhibit 
the binding of the mAb to the antigen and (2) it has to induce a humoral immune 
response that is directed to the natural antigen. 
 
At the beginning of the 1990’s, it was demonstrated that mimotopes were able to mimic 
discontinuous, i.e. conformational epitopes which are mainly recognized by antibodies 
[54,55]. Mimotopes can be found for proteins as well as for carbohydrates [56]. 
Furthermore, mimotopes can be identified with no prior information concerning 
antibody specificity [57,58]. 
Mimotopes of several tumor antigens have been generated and were used as vaccines in 
animal models. One of the first mimotopes of a tumor antigen was described for the 
prostate-specific membrane antigen [59]. A mAb recognizing an unknown antigen 
present on the surface of many tumor cells was used to generate a mimotope that was 
able to prolong the life span of animals inoculated with fibrosarcoma cells [60]. Two 
mAbs directed against the GD2 ganglioside, expressed on neuroectodermally derived 
tumors, including neuroblastoma and melanoma, were used in different studies to 
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generate mimotopes of the antigen. The vaccine-induced antibodies exhibited protection 
against human GD2-positive melanoma growth in the SCID mouse xenograft model 
[61] or induced a reduction of spontaneous liver metastases [62]. 
MAbs used in the clinic also served as sources to generate mimotopes of tumor 
antigens. Mimotopes of Her-2/neu were generated using trastuzumab [63,64], of 
epidermal growth factor receptor (EGFR) using cetuximab [65,66], and of CD20 using 
rituximab [67-70]. Some of these mimotopes [65-67] induced a humoral immune 
response able to inhibit tumor cell growth in vitro and are good candidates for active 
immunotherapy. 
For melanoma, Hafner et al. described mimotopes of the melanoma cell-adhesion 
molecule (Mel-CAM), which induced Mel-CAM specific antibodies in BALB/c mice. 
These antibodies showed an enhanced proliferation of the Mel-CAM positive human 
melanoma cell line MelJuSo in vitro. However, these antibodies mediated low but 
specific cell lysis of MelJuSo cells due to complement dependent cytotoxicity [71,72]. 
In regard to HMW-MAA, mimotopes were successfully identified using the mAb 
225.28S [73,74] and the mAb 763.74 [75], respectively. These mimotopes induced 
HMW-MAA specific antibodies that showed anti-tumor effects in vitro [73-75] as well 
as in vivo in a human melanoma xenotransplant SCID mouse model [76]. 
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Multi-epitope vaccines 
 
An interesting effect was observed in a study where SCID mice were treated with a 
combination of mAbs directed to Her-2/neu. The mixture was more effective than the 
individual mAbs indicating a synergistic effect [77]. Chen et al. observed similar results 
using a DNA vaccine containing four mimotopes of the MG7 antigen for gastric cancer 
in BALB/c mice [78]. Wagner et al. investigated the effect of a mixture of three 
peptides in a c-neu transgenic mouse model and observed higher inhibitions of tumor 
growth with the combination [79]. The authors concluded that targeting several epitopes 
of a tumor antigen with antibodies was more effective compared to a vaccine targeting 
only one epitope. 
This synergistic effect of targeting multiple epitopes of an antigen was not only 
investigated for human malignancies, but also for a viral disease of chicken. Wang et al. 
developed a multi-mimotope vaccine for infectious bursal disease virus, which induced 
high levels of antibodies upon immunization of chicken that showed protective effects 
against the viral infection [80]. 
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Aim of this thesis 
 
The aim of this study was the development of a mimotope-based polypeptide or 
polymimotope vaccine that would induce a strong humoral immune response against 
multiple epitopes of the HMW-MAA. Therefore, peptide ligands for a panel of anti-
HMW-MAA mAbs were planned to be selected using the phage display technology. 
These mAbs recognize distinct epitopes on the HMW-MAA and do not cross-inhibit 
each other. Phages displaying peptides that inhibit the binding of their corresponding 
mAb to the HMW-MAA should be selected as mimotopes. These mimotopes were 
planned to be synthesized and coupled to KLH as an immunogenic carrier protein. 
Immunization experiments were designed to be performed in BALB/c mice with either 
single mimotope conjugates or mixtures of mimotope conjugates. After purification of 
the induced mouse IgGs the in vitro effects of these mouse anti-HMW-MAA specific 
antibodies on HMW-MAA expressing melanoma cells should be assessed. Tumor 
proliferation, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement 
dependent cytotoxicity (CDC) should be studied. Finally, the in vivo efficacy of the 
antibodies induced by the mixture of mimotope conjugates that revealed the best in vitro 
results were planned to be tested and compared in a syngenic melanoma mouse model 
using C57BL/6 mice that harbor a subcutaneous tumor of the mouse melanoma cell line 
B16F10 which express the HMW-MAA upon transfection with HMW-MAA cDNA. 
 
With this study, the efficacy and superiority of poly- over single-mimotope vaccines in 
vitro and in vivo might be proven. The clinical use of mimotope vaccination might still 
take years, but we hope that this study provides insights towards a new way to prolong 
overall survival of melanoma patients and ultimately even to cure those patients. 
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Abstract 
The phage display technology has been successfully applied to study epitopes of a 
variety of antigens. Different libraries displaying random peptides fused to 
bacteriophage coat proteins have been developed. Peptide ligands selected from these 
libraries using monoclonal antibodies (mAbs) can mimic conformational epitopes which 
are recognized by the antibodies. In the recent past, such peptide mimics, also called 
mimotopes, have been used to develop antigen specific cancer vaccines. We have 
focused our research on the high molecular weight-melanoma associated antigen 
(HMW-MAA) which is highly expressed on melanoma cells. We screened five anti-
HMW-MAA monoclonal antibodies with different epitope specificities using a linear 
pIII-12mer phage display peptide library. Peptide ligands were selected by three 
different panning strategies: immobilization of the mAb (surface panning), protein G 
capture of the mAb, or streptavidin capture of the biotinylated mAb (solution-phase 
panning). Peptide ligands for each mAb could only be identified with the surface 
panning strategy. We therefore conclude that surface panning is superior to solution-
phase panning concerning a straight forward way to identify peptide ligands. 
 
 
Chapter II 
Successful selection of mimotopes from phage-displayed libraries strongly depends on the selection strategy  
38 
 
 
Chapter II 
Successful selection of mimotopes from phage-displayed libraries strongly depends on the selection strategy  
39 
Introduction 
The phage display technology uses both filamentous (e.g. M13, fd, f1) and, more 
recently, lytic bacteriophages (e.g. T4, T7, λ) to display foreign peptides or proteins on 
the phage surfaces (1). In the case of filamentous phages, the minor coat proteins pIII, 
pVI, pVII, and pIX as well as the major coat protein pVIII have been successfully used 
for peptide presentation (1). The coat proteins pIII and pVIII are commonly used to 
display random peptides fused to their N-terminus. Peptides are 4 to 40 amino acid (aa) 
residues in length, displayed either in linear or in constrained (circular) form (2). As 
large foreign peptides can disrupt the structural stability of the phages by hampering 
assembly and infection as a result of interference with pIII or pVIII function, they can 
only be displayed as hybrid phage particles (3,4). Therefore, phage display systems 
have been classified according to the arrangement of the coat protein genes into three 
different types: (1) type 3, (2) type 33, and (3) type 3+3 (the same applies to pVIII as 
well as pVI). Type 3 systems display foreign peptides on every copy of pIII. In type 33 
vectors, the phage genome bears two genes encoding for the wild-type and recombinant 
molecule. Type 3+3 systems have two genes for pIII on separate genomes, the wild-type 
version on a so called helper phage, the recombinant version on a phagemid (4). The 
latter two system types supply mosaic phages. 
Epitope study and other relevant research fields have been successfully investigated by 
using phage display (5-7). One attractive application of this technology is the 
identification of mimotopes which are small peptides that structurally mimic a given 
antibody-binding site but are composed of different amino acids (8). Mimotopes are 
able to mimic conformational epitopes both of protein and carbohydrate antigens (9), 
and should induce antibodies against the target antigen upon immunization. Therefore, 
they have been used in vaccines to induce immune responses against bacterial 
polysaccharides or tumor antigens. 
Regarding tumor antigen specific vaccines, several monoclonal antibodies (mAbs) 
directed against diverse tumor antigens have been used to identify mimotopes which 
were then investigated as vaccines. For malignant melanoma, the high molecular 
weight-melanoma associated antigen (HMW-MAA) has presented an interesting target 
antigen in the recent past. Mimotopes were identified using different phage display 
peptide libraries by screening several anti-HMW-MAA mAbs. The mAb 763.74 was 
screened with both a linear pVIII-15mer and a cyclic pVIII-12mer (XCX8CX) library 
(10), the mAb 149.53 with a linear pVIII-15mer library (11), and the mAb 225.28S with 
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a linear pVIII-9mer (12,13), a linear pVIII-15mer (11) as well as with a cyclic pIII-
12mer (CX10C) library (14). All studies followed a surface panning strategy, i.e. 
immobilization of the mAb by coating to a plastic surface, resulting in the identification 
of peptide ligands, except for the cyclic pVIII-12mer. 
Our intent was to identify peptide ligands for five different anti-HMW-MAA mAbs 
using surface as well as solution-phase panning strategies to evaluate under which 
conditions tight-binding peptides can be selected. Therefore, we have applied a 
commercially available phage display peptide library from New England BioLabs 
(Ipswich, MA, USA), which expresses 12-mer peptides at the N-terminus of the minor 
coat protein pIII of bacteriophage M13 (Ph.D.-12™). This library has been successfully 
used not only for the generation of mimotopes of tumor antigens (8,15) but also for 
epitope mapping of antibodies (16-18) as well as diverse other antigens (19-22). 
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Materials and Methods 
Monoclonal anti-HMW-MAA antibodies 
The mAbs VT80.12, VF1-TP34, 149.53, 225.28S F(ab')2,VF1-TP43 and TP61.5 were 
developed and characterized as described elsewhere (23-26). 
 
Biotinylation of mAbs 
NHS-LC-Biotin (Pierce, Rockford, IL, USA) was diluted in dimethylformamide at a 
concentration of 40 mg/ml. Five microliters of this solution was added to 1 mg/ml mAb 
in PBS and incubated for 45 min at room temperature (RT). Excess NHS-LC-Biotin 
was removed by dialysis against PBS. Successful biotinylation was proven by 
streptavidin detection in a dot blot assay. Briefly, biotinylated mAb was dotted onto a 
nitrocellulose membrane (Whatman, Dassel, Germany) and incubated with alkaline 
phosphatase (AP)-conjugated streptavidin (GE Healthcare, Little Chalfont, UK). Color 
development was done with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium. 
 
Cell lines 
The human melanoma cell line 518A2 which expresses high levels of HMW-MAA and 
M14, the human melanoma cell line with no detectable expression of HMW-MAA, 
were maintained in RPMI 1640 medium (Lonza, Verviers, Belgium). The medium was 
supplemented with 10% (v/v) FCS and 1% (v/v) antibiotic-antimycotic mix (both from 
Gibco, Paisley, UK). Both cell lines were cultured in a humidified atmosphere 
containing 5% CO2 and 95% ambient air at 37°C. 
 
Preparation of cell lysates 
A total of 5x107 melanoma cells was suspended in 1 ml of lysis buffer (50 mM Tris-
HCl, pH 7.4; 150 mM NaCl; 1% (v/v) Triton X-100; 1x complete EDTA-free protease 
inhibitor mix (Roche, Mannheim, Germany)), extensively vortexed and incubated on ice 
for 15 min. After disruption, samples were centrifuged 10 min at 800 x g at 4°C. 
Supernatants were removed from cell debris and stored at -20°C until use. Protein 
concentration was determined using a bicinchoninic acid (BCA) protein assay (Pierce). 
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Microsomal preparations 
Cells (~5x107) were disrupted in 1 ml lysis buffer (50 mM Na-phosphate, pH 7.4; 2 mM 
EDTA; 250 mM saccharose; 1x complete EDTA-free protease inhibitor mix (Roche)) 
using a dounce tissue grindler. Unbroken nuclei were separated by centrifugation at 
1000 x g. Thereafter, supernatants were centrifuged at 32000 x g for 1 h at 4°C. Pellets 
were solubilized in buffer containing 100 mM Na-phosphate, pH 7.4; 2 mM EDTA; 500 
mM NaCl and 1% Triton X-100. Samples were stored at 4°C until use. Protein 
concentration was determined using a BCA protein assay (Pierce). 
 
Biopanning 
The Ph.D.-12™ library that expresses linear 12mer peptides fused to the pIII minor coat 
protein of bacteriophage M13 was purchased from New England Biolabs (Ipswich, MA, 
USA). Biopanning protocols for surface and solution-phase panning were executed 
following the manufacturer’s instructions with some minor modifications. 
Surface panning (direct coating). 
MaxiSorp immunotubes (Nunc, Roskilde, Denmark) were coated with 10 µg mAb in 1 
ml 50 mM Na-carbonate buffer, pH 9.6, overnight (o/n) at 4°C. Unspecific binding sites 
were blocked with TBST (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.1% (v/v) Tween-
20) containing 3% (w/v) milk powder for 1 h at RT. Afterwards, the immobilized mAb 
was incubated with 1x1011 phages and 10 µg isotype control (BD Biosciences, Franklin 
Lakes, NJ, USA) in 1 ml TBST for 1 h at RT with agitation. Unbound phages and 
phage-isotype complexes were removed by extensively washing with TBST. Bound 
phages were eluted with 1 ml elution buffer (0.2 M Glycine-HCl, pH 2.2). The eluate 
was neutralized by adding 150 µl 1 M Tris-HCl, pH 9.1. 
Solution-phase panning with surface protein G capture. 
MaxiSorp immunotubes (Nunc) were coated with 20 µg protein G (AbD Serotec, 
Düsseldorf, Germany) in 1 ml 100 mM NaHCO3, pH 8.6 o/n at 4°C. Unspecific binding 
sites were blocked with 100 mM NaHCO3, pH 8.6 containing 5 mg/ml BSA for 1 h at 
4°C. Meanwhile, 1x1011 phages were preincubated with 10 µg mAb in TBST at RT. 
Protein G capture of the phage-mAb complex was allowed for 1 h at RT. Bound phages 
were eluted with 1 ml elution buffer (0.2 M Glycine-HCl, pH 2.2; 1 mg/ml BSA) and 
neutralized by adding 150 µl 1 M Tris-HCl, pH 9.1. An incubation step of phages with 
the isotype control was included for the 2nd as well as for the 3rd round of selection. 
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Solution-phase panning with surface streptavidin capture. 
MaxiSorp immunotubes (Nunc) were coated with 100 µg streptavidin in 1 ml 100 mM 
NaHCO3, pH 8.6 o/n at 4°C. Unspecific binding sites were blocked with 100 mM 
NaHCO3, pH 8.6 containing 5 mg/ml BSA and 0.1 µg/ml streptavidin for 1 h at 4°C. 
Meanwhile, 1x1011 phages were preincubated with 10 µg biotinylated mAb in TBST at 
RT. Streptavidin capture of the phage-biotinylated mAb complex was allowed for 30 
min at RT. Bound phages were eluted as described above for the solution-phase panning 
with surface protein G capture. 
 
For all three panning strategies, phages were amplified in E. coli ER2738. The 
amplified phages were purified by precipitation with 20% polyethylene glycol (PEG) 
6000, 2.5 M NaCl and used in the next round. Three rounds of selection were performed 
with increasing Tween-20 concentrations (1st round: 0.1%; 2nd round: 0.3%; 3rd round: 
0.5%). After that, individual plaques were picked up randomly of the unamplified 3rd 
round eluate to screen for specific single phage clones. 
 
Phage ELISA 
MaxiSorp immunoplates (Nunc) were coated with 5 µg/ml mAb in 50 mM Na-
carbonate buffer, pH 9.6 o/n at 4°C. Nonspecific binding sites were blocked with PBS 
containing 3% milk powder (3% MPBS). Phage precipitates were diluted in 3% MPBS, 
added to mAb-coated plates, and incubated for 1 h at RT. After washing with PBS, 
bound phages were detected using a horse radish peroxidase (HRP)-conjugated mouse 
anti-M13 antibody (GE Healthcare) diluted 1:5000 in 3% MPBS. Color development 
was carried out with o-phenylendiamin (Fast o-Phenylendiamin HCl; Sigma, St. Louis, 
MO, USA). The reaction was stopped by addition of 0.18 M H2SO4 and the absorbance 
was measured at 450 nm. 
 
ssDNA isolation and sequencing 
Single phage clones that bound specifically to the respective mAb were amplified in 
E.coli ER2738 (o/n-culture 1:100 diluted) for 4.5 h at 37°C with vigorous shaking. 
Bacterial cells were pelleted by centrifugation and single stranded DNA from each 
phage clone was isolated from 2 ml phage containing supernatant using the QIAprep 
Spin M13 Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
Agarose gel electrophoresis (1.2%) was carried out to check ssDNA integrity. PCR was 
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performed using the SequiTherm EXCEL II DNA Sequencing Kit (Epicentre 
Biotechnologies, Madison, WI, USA) with an IRD-800 labeled -96 gIII sequencing 
primer (5´- CCC TCA TAG TTA GCG TAA CG -3´; MWG Biotech, High Point, NC, 
USA). DNA sequence analysis was performed with an automatic LI-COR fluorescent 
sequencer 4000 L (LI-COR, Lincoln, NE, USA) and the AlignIR V2.0 software (LI-
COR). 
 
Competitive ELISA 
MaxiSorp immunoplates (Nunc) were coated with 5 µg/ml mAb in 50 mM Na-
carbonate buffer, pH 9.6 o/n at 4°C. Nonspecific binding sites were blocked with 3% 
MPBS. Phage particles (1011 pfu/well) and cell lysates (0.5, 1, and 1.5 mg/ml) were 
added simultaneously and incubated for 2 h at RT. After washing with PBS, bound 
phages were detected as described for phage ELISA. 
 
Synthesis of peptides 
The peptides NHLDTVMSLRLRC (80.12p3), NYQDLQRTHFKSGPGPGC (43.12p3), 
and an unrelated peptide AEGEFTRTQPGRFPGGGGGC (control peptide) were 
synthesized using F-moc strategy by piCHEM (Graz, Austria). The purity of the 
peptides was ~95%, as assessed by HPLC. 
 
ELISA inhibition assay 
Maxisorp immunoplates (Nunc) were coated o/n at 4°C with 4 µg/ml of mAb T61.5 in 
coating buffer (50 mM Na-carbonate, pH 9.6). Ten nanograms of biotinylated mAb was 
incubated with increasing concentrations (0, 10, 50, and 100 µg/ml) of synthetic peptide 
in TBST (0.5% Tween-20) containing 1% (w/v) BSA o/n at 4°C. The next day, 
microtiter plates were blocked with TBST/3% milk powder and incubated for 3 h at RT 
with 100 µg/ml microsomal preparations diluted in TBST/1% BSA. After washing, 
mAb preincubated with peptides was added and incubation was continued for one 
additional hour at RT. Bound biotinylated mAb was detected using AP-conjugated 
streptavidin (GE Healthcare), followed by addition of p-nitrophenylphosphate (Sigma). 
Absorbance was measured at 405 nm. Percentage of inhibition was calculated as 
follows: 100 – (OD (inhibited)/OD (uninhibited) x 100). 
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Sequence and structural alignments 
Identified peptide ligands were aligned with the HMW-MAA aa sequence (UniProt 
accession no. Q6UVK1) using the pairwise local alignment BLAST (27). 
Using the ModBase Database of Comparative Protein Structure Models (28), four 
models spanning the extracellular domain of HMW-MAA were chosen for mapping of 
mimotope residues onto the molecular surface of HMW-MAA using MIMOX, a Web 
Tool for Phage Display Analysis (29). Laminin alpha 2 chain LG4-5 domain pair (PDB 
accession no. 1dykA) was used as template to model aa 27-380 of HMW-MAA, the 
crystal structure of mammalian fatty acid synthase (PDB accession no. 2vz8B) for aa 
260-1733, the C-cadherin ectodomain (PDB accession no. 1l3wA) for aa 1259-1832, 
and the crystal structure of mammalian fatty acid synthase in complex with NADP 
(PDB accession no. 2vz9A) for aa 680-2234. 
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Results 
To select the positive clones that bind to the anti-HMW-MAA mAbs, a random 12-mer 
phage display peptide library composed of 1x1011 independent phage clones was 
incubated with the mAbs. For each biopanning, the phage titer of the amplified eluate 
was determined in plaque forming units (pfu) for inputs and outputs to determine the 
degree of selection. 
 
Surface panning with the mAb VT80.12 
After three rounds of selection, the total number of phages that bound to the mAb 
VT80.12 was increased from 3x105 pfu/ml in the 1st round to 2x109 pfu/ml in the 3rd 
round (Fig. 1A). Twenty-four individual phage clones were tested by phage ELISA for 
their binding ability to the mAb VT80.12 (Fig. 1B). Twenty-two positive clones were 
subjected to DNA sequencing yielding two predominant DNA sequences that encoded 
the aa sequences NHLDTVMSLRLR (“80.12p3”; eight phage clones) and 
HFYQFSLLNDMQ (“pVT80-2”; ten phage clones). Phage particles, expressing the two 
sequences, were co-incubated with a cell lysate from the HMW-MAA expressing 
human melanoma cell line 518A2 (HMW-MAApos) or the HMW-MAA negative human 
melanoma cell line M14 (HMW-MAAneg) on ELISA plate-immobilized mAb VT80.12. 
Only phages displaying the 80.12p3-peptide were competitively removed in a 
concentration-dependent way up to 35% (Fig. 2A). Therefore, the peptide 80.12p3 was 
chemically synthesized with an additional C-terminal cysteine residue for conjugation 
purposes. This peptide inhibited the binding of the biotinylated mAb VT80.12 to the 
HMW-MAA only up to 23% in an ELISA inhibition experiment (Fig. 2B). 
 
Surface panning with the mAb VF1-TP43 
Three rounds of selection were performed with the mAb VF1-TP43. The phage titer 
was increased from 1x105 pfu/ml in the 1st round to 3x109 pfu/ml in the 3rd round (Fig. 
3A). Thirty individual phage clones were tested for their specificity to the mAb VF1-
TP43 (Fig. 3B). Twenty positive clones were subjected to DNA sequencing yielding 
one DNA sequence encoding the aa sequence NYQDLQRTHFKS (“43.12p3”). In a 
competitive ELISA experiment, binding of the phage-displayed peptide was reduced up 
to 33% by a HMW-MAA containing cell lysate (Fig. 4A). The peptide 43.12p3 was 
synthesized with an GPGPG-linker and an additional C-terminal cysteine residue. It was 
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able to inhibit the binding of the biotinylated mAb VF1-TP43 to the HMW-MAA in a 
dose-dependent way up to 92% (Fig. 4B). 
 
Surface panning with the mAb VF1-TP34 
Three rounds of selection were performed with the mAb VF1-TP34 showing a distinct 
increase of the phage titer from 1x107 pfu/ml to 1x109 pfu/ml (Fig. 5A). Thereafter, 141 
individual clones were picked up randomly and tested in phage ELISA for their 
specificity. Only nine phage clones were able to bind specifically to the mAb VF1-
TP34. DNA sequencing yielded the two deduced aa sequences IICHPYPKRCVN 
(“pTP34-1”; eight individual clones) and SSTIQKHLETRR (“pTP34-2”; one clone). 
Both peptides (as phage-displayed peptides) were not competitively removed by a 
HMW-MAA containing cell lysate (data not shown). 
 
Surface panning with the mAb 149.53 
Four rounds of selection were performed with the mAb 149.53, because the increase of 
the phage titer was not sufficient after three rounds (Fig. 5B). Thereafter, the phage titer 
was increased from 2x106 pfu/ml to 1x109 pfu/ml. Overall, 118 individual clones of the 
fourth round were tested for their binding ability to the mAb 149.53. Twenty-six 
positive clones were subjected to DNA sequencing resulting in the one deduced aa 
sequence YVCPPMIHLCYS (“p149.53”). The binding of this phage-displayed peptide 
to the mAb 149.53 was not inhibited by a cell lysate from HMW-MAApos cells. 
 
Surface panning with the mAb 225.28S F(ab')2 
After three rounds of selection, the phage titer was increased from 2x106 pfu/ml in the 
1st round to 2x108 pfu/ml in the 3rd round (Fig. 5C). Twenty-four indiviudal phage 
clones were tested by phage ELISA for their binding ability to the F(ab')2-fragment of 
the mAb 225.28S. Twenty-three positive clones were subjected to DNA sequencing 
yielding one DNA sequence that encoded the aa sequence SWIHWNQADKLF 
(“p225Fab”). The binding of this phage-displayed peptide to the mAb 225.28S F(ab')2 
was not inhibited by a cell lysate from HMW-MAApos cells. 
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Identification of peptide ligands by solution-phase panning 
Due to the fact that direct coating of an antibody may alter its native 3-dimensional 
structure – although antibodies should bind preferentially with their Fc-part to the 
surface of microtiter plates – phage displayed peptides that could mimic conformational 
epitopes, which are recognized by the variable regions of an antibody, might not be 
identified. We therefore decided to perform the panning procedure under more native 
conditions for the mAbs, i.e. as solution-phase panning and used two different 
strategies. 
 
First, as protein G binds antibodies of the IgG1 isotype specifically via their Fc-part, 
this possibility seemed to be a very elegant one of identifying specific phages for our 
mAbs VT80.12, VF1-TP34, and 149.53. Therefore, protein G was immobilized and 
incubated with the mAb-phage complex. There was no increase of phage titer from the 
1st to the 3rd round (~107 pfu/ml for each round) and the amplified, precipitated phages 
from each round were negative for the respective mAb in phage ELISA experiments. 
 
In a second solution-phase panning procedure, streptavidin was immobilized to catch 
the biotinylated mAbs VT80.12 and VF1-TP34, respectively. Despite increasing phage 
titer (from ~106 pfu/ml in the 1st round to ~109 pfu/ml in the 3rd round), the amplified, 
precipitated rounds were not specific for the mAbs. 
 
Sequence and structure alignments 
The peptides 43.12p3 and p225Fab could be aligned to the extracellular domain of 
HMW-MAA at position 387-397 and 445-449, respectively, by BLAST (Fig. 6). No 
significant similarities were found for the other peptides. 
The peptide 80.12p3 could be located at position 570-527 of HMW-MAA using 
MIMOX (Table 1). Locations of the peptides 43.12p3, p225Fab, and 80.12p3 on the 
molecular surface of the HMW-MAA are illustrated in Fig. 7. 
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Discussion 
We have performed biopannings of five anti-HMW-MAA mAbs that recognize 
different epitopes of HMW-MAA described by lacking cross-reactivity to each other, 
using the Ph.D.-12™ library from New England BioLabs. Biopannings were performed 
in three ways: (1) surface panning/direct coating of the mAb, (2) solution-phase panning 
with surface protein G capture of the mAb, and (3) solution-phase panning with surface 
streptavidin capture of the biotinylated mAb, yielding different results regarding 
selection of peptide ligands for each panning strategy. 
At least one peptide sequence for each mAb was obtained with the surface panning 
protocol. Phages binding specifically to the mAb VT80.12 were easily obtained, 
resulting in two peptide ligands. Whereas the peptide 80.12p3 inhibited the binding of 
the mAb VT80.12 to the HMW-MAA (Fig. 2), the other peptide (pVT80-2) did not, 
indicating that the latter peptide did not mimic the antigen binding site of the mAb 
properly. As inhibitions obtained with the synthetic peptide 80.12.p3 were lower than 
the ones obtained with the phage-associated peptide, it is possible that the phage particle 
provides some inhibitory effects for this peptide. This can be explained by the fact that 
the interaction between the antibody and the phage-displayed peptide depends on the 
peptide’s microenvironment that is provided by the phage particle during the affinity 
selection (30). 
One peptide ligand was identified for the mAb VF1-TP43. All sequenced phage clones 
both from the 2nd (data not shown) and 3rd round (Fig. 3) displayed only this aa 
sequence indicating that this was the dominant peptide ligand for the mAb VF1-TP43. 
The peptide 43.12p3 inhibited the binding of HMW-MAA to the mAb VF1-TP43 both 
as phage-displayed peptide (Fig. 4A) and as synthetic peptide (Fig. 4B), excluding the 
possibility that the conformation of the phage-displayed peptide was constrained by the 
structural context of the bacteriophage surface. Furthermore, the additional GPGPG-
linker of the synthetic peptide might stabilize the peptide’s conformation leading to a 
higher inhibition obtained with the synthetic peptide than the phage-displayed one. 
These results clearly indicate that the synthetic peptide adopts a conformation in 
solution that is comparable with that on the phage surface (14). This proves that this 
mimotope is a genuine antigenic mimic of the HMW-MAA-epitope recognized by the 
mAb VF1-TP43. Hence, the peptide 43.12p3 will be considered as a mimotope 
candidate for immunization experiments to induce HMW-MAA specific antibodies. 
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Biopanning of the mAb VF1-TP34 was difficult yielding only ~6% positive individual 
phage clones displaying two peptide sequences. Peptide pTP34-1 contains two cysteine 
residues at position 3 and 10, which are likely to form a disulfide bridge, thus 
transforming the linear peptide into a circular one displayed on the phage particle. In 
our case, regarding coupling the synthetic peptide to an immunogenic carrier protein via 
an additionally introduced C-terminal cysteine residue for vaccination purposes, the 
chemical synthesis and the coupling process would only be possible with great effort. 
Due to this “unpreferable” sequence, the peptide pTP34-1 would be excluded for further 
examinations. As this peptide was more frequently found than the other peptide (pTP34-
2), the first seemed to be the dominant ligand obtained with the library used. However, 
both peptides did not inhibit the binding of HMW-MAA to the mAb VF1-TP34, 
indicating that these peptide ligands do not mimic the epitope. 
For the mAb 149.53 four rounds of selection were needed to obtain sufficient phage 
titers (Fig. 5B). After that, one peptide sequence containing two cysteine residues at 
position 3 and 10 could be obtained for all of the sequenced phage inserts. Therefore, 
the same conclusions can be made as for the peptide pTP34-1. 
With the F(ab')2-fragment of the mAb 225.28S one peptide sequence was obtained. 
Comparing this sequence to already described mimotopes identified with the mAb 
225.28S (11-14) revealed no sequence similarities. Peptide ligands obtained by Ferrone 
et al. (11), Hafner et al. (14), and Wagner et al. (13) yielded the same consensus 
sequence. We suggest that the F(ab')2-fragment, which binds properly to HMW-MAA, 
has a slightly different three-dimensional structure due to the missing Fc portion 
compared to the mAb 225.28S, thus preferring different types of peptide constraints. 
All identified peptides have one to four aromatic aa residues as well as many 
hydrophobic aa side chains, suggesting that they might partially mimic carbohydrate 
moieties, which would be in line with the fact that HMW-MAA is a highly glycosylated 
integral membrane chondroitin sulfate proteoglycan. The presence of both aromatic and 
hydrophobic residues is often a characteristic of peptides that mimic carbohydrates, 
resembling sugar moieties in their size and cyclic shape (31). However, local alignment 
or mimotope mapping of the peptides with the HMW-MAA sequence yielded matches 
for the peptides 43.12p3, p225Fab, and 80.12p3 (Fig. 6+7; Table 1), that could be 
allocated to surface-exposed residues of the extracellular domain of HMW-MAA. 
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Both solution-phase panning strategies either by protein G or streptavidin capture did 
not yield any specific peptide ligand. This might be attributed to restrictions regarding 
concentrations of either mAb or the catching molecules, incubation time, washing 
conditions as well as elution conditions, which affect the two important parameters of 
affinity selection, i.e. stringency and yield. 
We therefore conclude that screening a panel of several peptide libraries rather than just 
one and optimization of screening conditions should lead to the identification of high-
affinity peptides. It is possible that a single library will not provide tight-binding 
peptides for a lot of antibodies as the preference of an antibody for particular peptide 
ligands is usually not known in advance. 
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Tables 
Table 1 Mimotope mapping. The peptide 80.12p3 was mapped to the HMW-MAA 
surface using the conservative match mode of the web tool MIMOX (29). The crystal 
structure of mammalian fatty acid synthase (PDB accession no. 2vz8B) was used to 
model aa 260-1733 of HMW-MAA. 
aa position 570 568 566 567 569 565 563 561 541 536 534 527
HMW-MAA Q H L E T I M S L R L R 
80.12p3 N H L D T V M S L R L R 
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Figures 
Fig. 1 Specificity of phages selected for the mAb VT80.12. Amplified panning rounds 
(A) and 24 selected single phage clones (B) were tested for their specificity to the mAb 
VT80.12 ( ) or a mouse IgG1 isotype control ( ) in phage ELISA experiments. 
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Fig. 2 Mimicry of the phage-displayed peptide “80.12p3”. (A) In a competitive ELISA 
experiment, the binding of the phage-displayed peptide 80.12p3 to the mAb VT80.12 
was competed by a cell lysate from HMW-MAApos cells ( ) but not from HMW-
MAAneg cells ( ). (B) Microtiter plates were coated with the mAb TP61.5 and 
incubated with a microsomal preparation of 518A2 melanoma cells to catch the HMW-
MAA. Biotinylated mAb VT80.12 was preincubated with increasing concentrations of 
synthetic peptide 80.12p3 ( ) and a control peptide ( ), and then incubated with the 
HMW-MAA. Percentage of inhibition was calculated as follows: 100 – (OD 
(inhibited)/OD (uninhibited) x 100). 
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Fig. 3 Specificity of phages selected for the mAb VF1-TP43. Amplified panning rounds 
(A) and 30 selected single phage clones (B) were tested for their specificity to the mAb 
VF1-TP43 ( ) or a mouse IgG1 isotype control ( ) in phage ELISA experiments. 
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Fig. 4 Mimicry of the phage-displayed peptide “43.12p3”. (A) A cell lysate from 
HMW-MAApos cells ( ) but not from HMW-MAAneg cells ( ) was able to compete the 
binding of the phage-displayed peptide 43.12p3 in a concentration dependent way. (B) 
Graph showing percentage of inhibition as calculated from reduction in binding ability, 
when biotinylated mAb VF1-TP43 was preincubated with increasing concentrations of 
synthetic peptide 43.12p3 ( ) and a control peptide ( ) ,and then incubated with the 
HMW-MAA. 
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Fig. 5 Specificity of phages selected for the mAbs VF1-TP34 (A), 149.43 (B), and 
225.28S F(ab')2 (C). Amplified panning rounds were tested for their specificity to the 
respective mAb ( ) and isotype-matched control antibody ( ). 
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Fig. 6 Local alignment of identified peptide ligands with HMW-MAA. The sequences 
of the peptides 43.12p3 (magenta) and p225Fab (cyan) could be aligned with HMW-
MAA (UniProt accession no. Q6UVK1) using BLAST (27). Identical residues are 
indicated in bold, similar ones in italics. The length of the whole peptide sequences is 
indicated with colored solid lines. The signal peptide and the transmembrane region of 
HMW-MAA are indicated in bold and underlined letters at the N-terminus and C-
terminus, respectively. 
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Fig. 7 Mimotope mapping. The peptides 43.12p3 (magenta), p225Fab (cyan), and 
80.12p3 (yellow) are displayed on the putative surface of HMW-MAA using Swiss 
PDB Viewer (Swiss Institute of Bioinformatics, Lausanne, Switzerland). The crystal 
structure of mammalian fatty acid synthase (PDB accession no. 2vz8B) was used to 
model aa 260-1733 of HMW-MAA. 
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Abstract 
Vaccines based on peptide mimics (mimotopes) of conformational tumor antigen 
epitopes have been investigated for a variety of human tumors including breast cancer, 
tumors expressing the carcinoembryonic antigen, B cell lymphoma, neuroblastoma, and 
melanoma. In our previous work, we designed a vaccine based on a mimotope of the 
high molecular weight-melanoma associated antigen (HMW-MAA) that elicited HMW-
MAA specific antibodies with anti-tumor activity in vitro and in vivo. In this study, we 
aimed to identify additional HMW-MAA mimotopes with distinct epitope specificities 
as potential components of a polymimotope melanoma vaccine. 
Random peptide phage libraries were screened with the anti-HMW-MAA monoclonal 
antibodies (mAbs) VT80.12 and VF1-TP43 yielding one peptide ligand for each mAb. 
Both peptides confirmed epitope mimicry in inhibition ELISAs and were coupled to the 
carrier protein keyhole limpet hemocyanin (KLH) for immunization experiments. 
Although both HMW-MAA mimotopes elicited peptide specific antibodies in rabbits or 
BALB/c mice, HMW-MAA specific antibodies were only obtained in mice upon 
immunization with the mimotope defined by the mAb VT80.12. However, despite being 
cross-reactive to HMW-MAA these antibodies had no effect on the in vitro tumor 
proliferation of HMW-MAA expressing human melanoma cells. 
This work describes constraints related to mimotopes generated by phage display and 
discusses the potential relevance of mimotope-selecting mAbs and applied 
immunization models on the outcome of mimotope vaccination. From our results we 
conclude that these aspects should be considered when using mimotopes as vaccine 
components. 
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1. Introduction 
For at least two decades, the high molecular weight-melanoma associated antigen 
(HMW-MAA) has been the focus of several studies to implement effective 
immunotherapy for melanoma. Originally identified with murine monoclonal antibodies 
(mAbs) on the surface of human melanoma cells, HMW-MAA has been found to be 
overexpressed in at least 80% of primary and metastatic melanomas and more recently, 
in several other tumors as well as cancer stem cells 1,2. However, HMW-MAA 
expression is not restricted to transformed cells, as it has been found on various cells of 
normal tissue including melanocytes, hairfollicles and basal cells of the epidermis as 
well as endothelial cells, chondrocytes and pericytes 1. Its expression on both activated 
and resting pericytes in tumor vessels has suggested that HMW-MAA is critical to 
tumor angiogenesis 2. Furthermore, HMW-MAA is known to contribute to the 
malignant phenotype of melanoma by activating several signaling cascades (e.g. Rho 
GTPases, p130cas, FAK) that are involved in adhesion, migration and spreading of 
melanoma cells 3. 
The idea of HMW-MAA-directed immunotherapy has been primarily supported by 
preclinical studies that showed prolonged survival rates of melanoma patients in 
association with anti-HMW-MAA specific antibodies (Abs) induced by active 
immunization 4-6. Since then, a number of antibody- as well as T cell-based 
immunotherapies have been investigated. Recently, Maciag et al. generated a Listeria 
monocytogenes (Lm)-based vaccine against HMW-MAA 7. Immunization of C57BL/6 
mice bearing B16F10-HMW-MAA melanomas induced HMW-MAA specific CD8+ 
and CD4+ T cells that were equally required for tumor inhibition, as in vivo depletion of 
each of these cells resulted in uncontrolled tumor growth 7. Noteworthy, this study 
provided the first syngenic melanoma mouse model for HMW-MAA as well as novel 
information on the contribution of T cells in anti-HMW-MAA immunity. 
In contrast, we emphasized the induction of humoral anti-HMW-MAA immunity by 
using peptide mimics (mimotopes) as immunogens. Mimotopes are small peptides that 
mimic conformational B cell epitopes of antigens and can be selected by screening 
random peptide phage libraries with a mAb of interest. As mimotopes do not 
necessarily share the identical amino acid sequence with the original antigen, they are 
ideal antigen surrogates able to overcome immunotolerance 8-11. Regarding melanoma, 
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this is of particular interest as most melanoma associated antigens including the HMW-
MAA are known to be self-antigens 1,12. 
In previous studies, we identified a linear HMW-MAA mimotope (225D9.2+) which 
mimics an epitope recognized by the anti-HMW-MAA mAb 225.28S. Immunization 
with this mimotope coupled to tetanus toxoid induced HMW-MAA specific Abs in 
rabbits that inhibited tumor cell proliferation in vitro 13. Passive administration of these 
Abs in a xenogenic melanoma SCID mouse model inhibited tumor growth up to 40% in 
a therapeutic setting and up to 62% in a prophylactic setting 14. 
As epitope loss is commonly found in melanoma 15 and several studies indicate that 
targeting multiple epitopes of a tumor antigen has synergistic effects and correlates with 
higher success rates, efficacy of a melanoma vaccine might be improved by the co-
application of several peptides 16-18. 
In this study, we report the selection of additional HMW-MAA mimotopes with distinct 
epitope specificities and discuss constraints related to mimotope vaccines regarding 
their immunogenicity and antigenicity. 
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2. Materials and methods 
2.1. Monoclonal anti-HMW-MAA antibodies 
The mAbs VT80.12, VF1-TP43, and TP61.5 were developed and characterized as 
described elsewhere 19-21. 
2.2. Biotinylation of Abs (mAbs, rabbit IgGs) 
NHS-LC-Biotin (Pierce, Rockford, IL, USA) was diluted in dimethylformamide at a 
concentration of 40 mg/ml. Five microliters of this solution was added to 1 mg/ml mAb 
or rabbit IgGs in PBS and incubated for 45 min at room temperature (RT). Excess NHS-
LC-Biotin was removed by dialysis against PBS. 
2.3. Cell lines 
The human melanoma cell line 518A2 which expresses high levels of HMW-MAA and 
M14, a human melanoma cell line with no detectable expression of HMW-MAA, were 
maintained in RPMI 1640 medium (Lonza, Verviers, Belgium). The medium was 
supplemented with 10% (v/v) FCS and 1% (v/v) antibiotic-antimycotic mix (both from 
Gibco, Paisley, UK). Both cell lines were cultured in a humidified atmosphere 
containing 5% CO2 and 95% ambient air at 37°C. 
2.4. Microsomal preparations 
Microsomal preparations were performed using ~5x107 cells according to the protocol 
described elsewhere 22. Protein concentration was determined using a bicinchoninic acid 
(BCA) protein assay (Pierce). 
2.5. Phage display, affinity selection and sequence analysis 
Peptide ligands for the mAb VT80.12 were selected from a pVIII-15mer phage display 
peptide library 23. Therefore, the mAb VT80.12 was immobilized and incubated with 
~1010 phages. Phages displaying peptides that bound to the mAb VT80.12 were eluted 
and amplified in E. coli TG1. 
Peptide ligands for the mAb VF1-TP43 were selected using the Ph.D.-12™ Phage 
Display Peptide Library, a pIII-12mer library, purchased from New England Biolabs 
(Ipswich, MA, USA). Biopanning was executed following the manufacturer’s 
instructions. 
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After three rounds of selection, single phage clones that bound to the respective mAb 
were identified by phage ELISA and subsequently subjected for DNA sequencing. 
2.6. Synthesis of peptides 
The peptides GRQYYEGRKPDYRAAC (15/3/6) and NYQDLQRTHFKSGPGPGC 
(43.12p3) were synthesized using F-moc strategy by piCHEM (Graz, Austria). The 
purity of the peptides was ~95%, as assessed by HPLC. 
2.7. ELISA inhibition assay 
MaxiSorp immunoplates (Nunc, Rosklide, Denmark) were coated overnight (o/n) at 4°C 
with 4 µg/ml of mAb T61.5 in 50 mM Na-carbonate buffer, pH 9.6. Ten nanograms of 
biotinylated mAb were incubated with increasing concentrations (0, 10, 50, 100, and 
500 µg/ml) of synthetic peptides in TBST (0.5% (v/v) Tween-20) containing 1% (w/v) 
BSA o/n at 4°C. After blocking with TBST/3% (w/v) milk powder, plates were 
incubated for 3 h at RT with 100 µg/ml microsomal preparations diluted in TBST/1% 
BSA. After washing, the mAb preincubated with peptides was added and incubation 
was continued for an additional hour at RT. Bound biotinylated mAb was detected 
using alkaline phosphatase (AP)-conjugated streptavidin (GE Healthcare, Little 
Chalfont, UK), followed by addition of p-nitrophenylphosphate (Sigma). Absorbance 
was measured at 405 nm. Percentage of inhibition was calculated as follows: 100 – (OD 
(inhibited)/OD (uninhibited) x 100). 
2.8. Conjugation of peptides 
Peptides were coupled to the carrier protein keyhole limpet hemocyanin (KLH; Sigma, 
St. Louis, MO, USA) or bovine serum albumin (BSA; Pierce) using the 
heterobifunctional crosslinker reagent m-maleimidobenzoyl-N-hydroxysuccinimide 
(MBS; Pierce) as described previously 13. Conjugation of the peptides to the carrier 
proteins was verified in a dot blot assay. Therefore, peptide conjugates were dotted onto 
nitrocellulose (NC) membrane (Whatman, Dassel, Germany). After blocking with 
PBST (0.5% Tween-20) containing 3% milk powder, NC strips were incubated with 
biotinylated mAb, followed by AP-conjugated streptavidin (GE Healthcare). Color 
development was done with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue 
tetrazolium. 
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2.9. Immunizations 
New Zealand white rabbits were immunized at Charles River Laboratories (Kisslegg, 
Germany). Immunizations were done thrice in 14- to 28-day intervals (day 1, 29, and 
43) each with 200 µg of the peptide-KLH conjugates or KLH alone adsorbed to CFA 
(first immunization) or IFA (second and third immunization). Serum samples were 
taken before treatment (preimmune serum) and ten days after the first (day 11) and 
second immunization (day 39). Rabbits were sacrificed two weeks after the third 
immunization (day 57). 
Female BALB/c (4 groups, n = 3; 6-8 weeks old; Charles River Laboratories, Sulzfeld, 
Germany) were immunized i.p. three times in 14-day intervals (day 1, 15, and 29) each 
with 15 µg of the peptide-KLH conjugates or KLH alone adsorbed to aluminium 
hydroxide (Alum; Serva, Heidelberg, Germany) in a total volume of 150 µl PBS 
solution. Sham-treated mice received PBS buffered alum only. Sera were taken from the 
tail vein on day 0 (preimmune serum), 22, and 41. Mice were treated according to 
European Union Rules of Animal Care, with permission 66.009/152-II/10b/2009 from 
the Austrian Ministry of Science. 
2.10. Purification of rabbit or mouse IgG Abs 
Total IgG from sera of rabbits were purified according to the protocol described 
elsewhere 13. 
For purification of mouse IgG Abs, serum samples taken after the third immunization or 
after sacrifice of mice were pooled for each group and diluted with an equal volume of 
binding buffer (20 mM Na-phosphate, pH 7.0). The HiTrap Protein G HP column (GE 
Healthcare) was equilibrated with binding buffer and the sample applied. Bound Abs 
were eluted with 100 mM glycine-HCl, pH 2.7 and neutralized by addition of 1 M Tris-
HCl, pH 9.0. 
Purification of rabbit or mouse IgG was monitored using nonreducing 8% SDS-PAGE. 
Protein concentration was determined by a BCA protein assay (Pierce). 
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2.11. Peptide specific Ab response 
MaxiSorp immunoplates (Nunc) were coated with 10 µg/ml peptide-BSA conjugates or 
KLH or BSA in 50 mM Na-carbonate buffer, pH 9.6, o/n at 4°C. Nonspecific binding 
sites were blocked with TBST/3% milk powder. 
Purified rabbit Abs were diluted at concentrations of 0.05, 0.1, 0.5, 1, 5, and 10 µg/ml in 
TBST/0.5% BSA, added to antigen-coated plates, and incubated for 2 h at RT. After 
washing, bound Abs were detected using AP-conjugated swine anti-rabbit IgG (Dako, 
Glostrup, Denmark) diluted 1:1000 in TBST/0.5% BSA. Color development was 
performed as described for the ELISA inhibition assay. 
Mouse sera were diluted 1:1000 in TBST/0.5% BSA and incubated for 2 h at RT. AP-
conjugated rabbit anti-mouse IgG + IgM (Jackson ImmunoResearch, West Grove, PA, 
USA) diluted 1:5000 in TBST/0.5% BSA was used as a second step Ab. Visualization 
of bound mouse Abs was performed as described above. 
2.12. HMW-MAA specific Ab response 
2.12.1. ELISA protocol 
For the detection of the HMW-MAA specific Ab response, HMW-MAA was purified 
from microsomal preparations as described for the ELISA inhibition assay. After 
blocking and catching, plates were incubated for 2 h at RT with increasing 
concentrations (12.5, 50, and 200 µg/ml) of purified rabbit Abs diluted in TBST/1% 
BSA. Bound IgG was detected as described for the peptide-specific Ab response. 
2.12.2. FACS protocol 
Flow cytometric analysis of melanoma cells stained with sera from immunized mice or 
purified Abs from immunized rabbits was performed as previously described 24. Briefly, 
5x105 cells were incubated for 1 h on ice with a 1:10 dilution of pooled mouse sera for 
each group or 100 µg purified rabbit Abs in 100 µl PBS/1% BSA. One microgram of 
mAb VT80.12 served as positive control staining of HMW-MAA. Cells were then 
washed twice with PBS/0.5% BSA and incubated for an additional 30 min on ice with 
FITC-labeled goat anti-mouse IgG or FITC-labeled goat anti-rabbit IgG (both diluted 
1:2000 in PBS/1% BSA; AbD Serotec, Düsseldorf, Germany). After washing, cells 
were resuspended in PBS/0.5% BSA and 20,000 gated events were analyzed by flow 
cytometry on a BD FACScanto using BD FACSDiva software (BD Biosciences, 
Chapter III 
Specificity of mimotope-induced anti-HMW-MAA antibodies does not ensure biological activity  
79 
Franklin Lakes, NJ, USA). Histogram overlays were done applying FlowJo software 
(Tree Star, Ashland, OR, USA). 
2.12.3. Immunohistochemistry (IHC) protocol 
Immunohistochemical staining of established 518A2 tumor tissues was performed as 
described by Wagner et al. 14. Briefly, tumor sections were incubated with either 
blocking buffer (negative control), 30 µg/ml biotinylated mAb VT80.12 (positive 
control) or 100 µg/ml biotinylated purified Abs of rabbits either immunized with 
15/3/6-KLH conjugate or KLH. After washing with TBST, slides were incubated with 
StreptABComplex/HRP (Dako) for 30 min. Specific Ab binding was visualized by a 
DAB chromogen solution (Dako) following hematoxylin counterstaining. Stained slides 
were viewed by an Olympus Vanox AHBT3 microscope and photographed with a Zeiss 
AxioCam MRc5 camera. 
2.13. Inhibition of tumor cell growth in vitro 
Tumor cells were seeded in 96-well tissue culture plates (Costar; Corning, NY, USA) at 
1500 cells/well. Cells were allowed to adhere o/n at 37°C. Purified Abs from mice 
immunized with either the 15/3/6-KLH conjugate or KLH were added at increasing 
concentrations (0, 0.01, 0.1, and 1 mg/ml) and incubation was continued for an 
additional 72 h at 37°C. Cells were pulsed with 0.5 µCi of [methyl-3H]thymidine/well 
(GE Healthcare) for another 6 h at 37°C and then harvested. Incorporated [3H]thymidine 
was measured by a Wallac MicroBeta TriLux 1450 counter (PerkinElmer, Waltham, 
MA, USA). Percentage of inhibition of proliferation was calculated by comparing the 
cpm values of treated cells with those of untreated cells, which were set at 100%. 
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3. Results 
3.1. Identification of peptide ligands 
Biopanning of the mAb VT80.12 was performed with a linear pVIII-15mer phage 
display peptide library. After three rounds of selection, the total number of phages that 
bound to the mAb VT80.12 was increased from 1x105 CFU/ml in the 1st round to 1x109 
CFU/ml in the 3rd round. Twenty individual phage clones of each the 2nd and 3rd round 
were tested for their ligand specificity in phage ELISA. Among these, eighteen (2nd 
round) and nineteen (3rd round) phage clones bound to the mAb VT80.12. DNA 
sequencing of these 37 phage clones yielded one peptide sequence 
GRQYYEGRKPDYRAA (“15/3/6”). Phages (106-1013 CFU/ml) displaying this 
sequence showed a concentration-dependent inhibition up to 70% in ELISA 
experiments (data not shown). Therefore, the peptide 15/3/6 was chemically synthesized 
with an additional C-terminal cysteine residue for conjugation purposes. In ELISA 
inhibition experiments, the peptide inhibited the binding of the mAb VT80.12 to the 
HMW-MAA up to 93% (Fig. 1A). 
Biopanning of the mAb VF1-TP43 was performed with a linear pIII-12mer phage 
display peptide library. Three rounds of selection yielded an increase of phage titer from 
1x105 pfu/ml (1st round) to 3x109 pfu/ml (3rd round). Among 30 tested phage clones, 20 
were specifically recognized by the mAb VF1-TP43 in phage ELISA. DNA sequencing 
yielded one peptide sequence NYQDLQRTHFKS (“43.12p3”). In a competitive ELISA 
experiment, binding of the phage displayed peptide to the mAb VF1-TP43 was reduced 
up to 33% by a HMW-MAA containing cell lysate (data not shown). The peptide 
43.12p3 was synthesized with a GPGPG-linker and an additional C-terminal cysteine 
residue. In subsequent inhibition experiments, this peptide inhibited the binding of the 
mAb VF1-TP43 to the HMW-MAA up to 100% (Fig. 1B). 
3.2. Peptide specific Ab response in rabbits 
The peptide 15/3/6 was coupled to KLH or BSA as carrier protein. Conjugation to the 
carrier protein was confirmed in a dot blot assay (data not shown). New Zealand white 
rabbits were immunized with the conjugate 15/3/6-KLH or the carrier protein KLH 
alone. After three immunizations, Abs were purified using a HiTrap protein A HP 
column. Twenty milliliters of serum yielded ~20 mg of IgG Abs. The purity was greater 
than 95% as confirmed by SDS-PAGE (data not shown). Peptide specific Abs were 
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determined by ELISA after incubation of coated peptide-BSA conjugate, BSA or KLH 
with purified IgG Abs. Both, 15/3/6- and KLH-specific Abs were already detectable at a 
concentration of 0.05 µg/ml and increased in a dose- dependent manner (Fig. 2). Abs 
purified from the KLH-immunized rabbit did not bind to the peptide. No Abs directed 
against BSA could be determined. 
3.3. HMW-MAA specific Ab response in rabbits 
HMW-MAA specificity of rabbit Abs was determined in ELISA by testing their binding 
ability to the HMW-MAA. Binding to the HMW-MAA negative cell line M14 was 
detected for both, the peptide-conjugate and the KLH-induced Abs (Fig. 2). Even when 
the HMW-MAA catching mAb was directly incubated with purified rabbit Abs and 
subsequently detected with AP-conjugated swine anti-rabbit IgG, high background 
levels were measured (data not shown). 
In a second approach, HMW-MAA specificity of rabbit Abs was investigated by FACS 
analysis. The HMW-MAA positive human melanoma cell line 518A2 (HMW-MAApos) 
or the HMW-MAA negative human melanoma cell line M14 (HMW-MAAneg) were 
incubated with each 100 µg purified rabbit Abs and detected with a FITC-conjugated 
goat anti-rabbit IgG. As expected, the mAb VT80.12 specifically bound to the HMW-
MAApos, but not to the HMW-MAAneg cells. However, HMW-MAA specificity of the 
15/3/6-KLH conjugate induced Abs could not be observed, as Abs induced by KLH 
showed a similar staining pattern to HMW-MAApos as well as to HMW-MAAneg cells 
(Fig. 3A). 
In a third approach, we used solid 518A2 tumors established in C.B.17 SCID/SCID 
mice 14 to detect HMW-MAA reactive rabbit Abs by IHC. Whereas staining of 
melanoma cells was observed with the biotinylated mAb VT80.12, none was observed 
with either an isotype-matched control mAb (data not shown) or PBS buffer. Also in 
this setup, we detected a high background staining of anti-KLH Abs on 518A2 tumor 
tissue, and therefore no HMW-MAA specific anti-15/3/6 Abs (Fig. 3B). 
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3.4. Peptide specific Ab response in BALB/c mice 
The peptides 15/3/6 or 43.12p3 were coupled each to KLH or BSA. Female BALB/c 
mice (4 groups, n = 3) were immunized with 15 µg of the peptide-KLH conjugates, 
KLH or were sham-treated with PBS buffered alum. Serum samples of each group were 
tested for the presence of peptide specific Abs in ELISA. Peptide specificity was 
confirmed for both anti-15/3/6-KLH and anti-43.12p3-KLH Abs as they bound to the 
corresponding peptide-BSA conjugates (Fig. 4). As expected, KLH specific Abs were 
detected in the KLH-group (Fig. 5) as well as in the groups immunized with the 
peptide-KLH conjugates (data not shown). Sham-treated mice did not develop Abs 
against the peptides 15/3/6 or 43.12p3, KLH or BSA (data not shown). 
3.5. HMW-MAA specific Ab response in BALB/c mice 
Preimmune serum samples or serum samples after the third immunization of individual 
mice were pooled for each group. Serum pools were diluted 1:10 and incubated with 
HMW-MAApos or HMW-MAAneg cells. Bound Abs were detected with a FITC-labeled 
goat anti-mouse IgG by FACS analysis. None of the mouse Abs of preimmune serum 
pools showed reactivity to HMW-MAApos or HMW-MAAneg cells (data not shown). 
Immunization with the 15/3/6-KLH conjugate induced HMW-MAA specific Abs, 
whereas the 43.12p3-KLH conjugate did not (Fig. 5). KLH-induced Abs showed 
negligible background staining on HMW-MAApos as well as HMW-MAAneg cells. 
3.6. Inhibition of tumor cell growth 
The effect of anti-15/3/6-KLH Abs on tumor growth in vitro was determined by a 
[3H]thymidine proliferation assay. HMW-MAApos or HMW-MAAneg cells were 
incubated with increasing concentrations of purified mouse Abs. Upon treatment with 
anti-15/3/6 Abs, proliferation of HMW-MAApos cells was inhibited to a maximum of 
~17% (Fig. 6). Almost identical results were obtained, when either HMW-MAApos cells 
were treated with anti-KLH Abs or HMW-MAAneg cells were incubated with anti-
15/3/6 or anti-KLH Abs. Results given in Fig. 7 represent mean values of 3 independent 
experiments. 
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4. Discussion 
In this study we aimed to select two mimotopes defined by the anti-HMW-MAA mAbs 
VT80.12 and VF1-TP43 that should serve together with our previously described 
225D9.2+ mimotope 13,14 as components of a polymimotope vaccine against melanoma. 
We therefore screened two linear phage display peptide libraries (pVIII-15mer with 
mAb VT80.12, pIII-12mer with mAb VF1-TP43) yielding one peptide ligand for each 
mAb. Both peptides (15/3/6: ligand to VT80.12; 43.12p3: ligand to VF1-TP43) 
inhibited binding of the respective mAb to the HMW-MAA up to 100%, thereby 
proofing epitope mimicry and their definition as mimotopes. Upon immunization of 
either rabbits or BALB/c mice, each mimotope coupled to the carrier protein KLH 
demonstrated immunogenicity by inducing mimotope specific Abs. However, only the 
15/3/6-KLH conjugate induced HMW-MAA specific Abs in BALB/c mice, but these 
Abs failed to inhibit tumor cell proliferation in vitro. 
 
Epitope mimicry to HMW-MAA was confirmed for both peptides 15/3/6 and 43.12p3 
in ELISA inhibition experiments (Fig. 1). Thus, constraints referring to phage display 
were preliminary excluded. 
An important issue of this study was the applied animal model in the context of the 
carrier protein used for vaccination. Initially, immunization experiments were 
performed in rabbits as high amounts of antibodies can be obtained from the blood for 
subsequent in vitro tests. Although mimotope specific Abs were induced for the tested 
mimtope, these showed no HMW-MAA specificity in ELISA experiments (Fig. 2). 
Instead, we observed a high background staining of KLH specific Abs on the HMW-
MAA-positive or -negative cell lysate, as well as on the HMW-MAA catching mAb. 
Similarly, FACS staining (Fig. 3) as well as immunohistochemistry (Fig. 4) failed to 
confirm HMW-MAA specific Abs. Immunizations were then repeated in BALB/c mice 
to assess whether the results from the rabbit immunizations were attributed to the carrier 
protein KLH or the applied animal model. Using this model, FACS analysis confirmed 
HMW-MAA specificity of mimotope-induced Abs (Fig. 6), indicating that the 
undesired binding of rabbit anti-KLH Abs was likely attributed to the rabbit Abs and 
not to the carrier protein KLH. However, we cannot exclude a possible contribution of 
the used adjuvants (CFA/IFA in rabbits vs. alum in BALB/c mice) to the unspecific 
binding of rabbit anti-KLH Abs, as adjuvants are known to differentially deliver antigen 
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and activate the immune system 25. We therefore conclude that the choice of carrier 
protein has an impact on the outcome of vaccination and might depend on the used 
immunization model. 
Although the 43.12p3-KLH conjugate induced mimotope specific mouse Abs, these 
failed to cross-react with the natural antigen HMW-MAA (Fig. 6), indicating that 
immunogenicity of mimotopes does not necessarily correlate with their specificity. The 
discrepancy between epitope specificity of an anti-HMW-MAA mAb and epitope 
specificity of HMW-MAA mimotope-induced Abs is best described by previous studies 
of Wagner et al. 13 and Hafner et al. 26. Both studies deal with the identification of 
distinct HMW-MAA mimotopes which were defined by the same mAb (225.28S) and 
coupled to the same carrier protein (tetanus toxoid, TT) for subsequent immunization 
experiments in rabbits. Using the identical immunization protocol, a HMW-MAA 
specific Ab response was only obtained upon immunization with the mimotope-TT 
conjugate described by Wagner et al. 13. These findings clearly indicate that – despite 
conforming affinity selections as well as conforming immunization protocols – not 
every mimotope truly mimics the relevant epitope of the original antigen. On the one 
hand, such constraints might originate during affinity selection as phage displaying 
peptides may bind to residues of the mAb that are not part of the paratope. Although 
such peptides might inhibit the binding of their defined mAb to the original epitope, 
these will fail to induce a specific immune response to the original antigen. In addition, 
B cell epitopes are known to be conformational in nature 27. Hence, it is possible that 
mAbs recognize certain conformations of epitopes which are not displayed in the same 
structural context by the natural antigen. The above-described constraints probably 
outline the major pitfall of the phage display technique that complicates the selection of 
“true“ mimotopes, solely based on their binding characteristics to mAbs. On the other 
hand, it is to state that immunization with mimotopes does not guarantee the induction 
of Abs that display the appropriate paratope to the natural antigen, emphazising also a 
possible contribution of the used animal model to the outcome of mimotope 
vaccination. This might be of particular relevance for other investigators who apply 
mimotopes for vaccination strategies. 
Immunization of BALB/c mice with the 15/3/6 mimotope conjugate resulted in the 
induction of mimotope- and HMW-MAA specific Abs (Fig. 5 and 6). However, these 
Abs showed no anti-tumor activity in in vitro proliferation assays (Fig. 7). Importantly, 
the mAb VT80.12 itself does not inhibit tumor cell proliferation neither directly nor 
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indirectly by mediating ADCC or CDC 28. We therefore have to question whether anti-
tumor activity in vivo of the mimotope defining mAb should be a prerequisite to induce 
antibodies with tumor inhibiting properties. As a matter of fact, certain mAbs (e.g. 
Rituximab 29-32, Cetuximab 33,34, Trastuzumab 11,35) which are currently applied for 
cancer therapies and successfully served as sources to generate mimotope vaccines with 
anti-tumor activity in vitro fulfill this requirement even if in vivo results for the these 
mimotope vaccines are not available yet. As reported by Hafner et al., passive 
administration of the anti-HMW-MAA mAb 225.28S significantly reduced tumor 
volume in a human melanoma xenotransplant SCID mouse model, although this mAb 
had no effect on human melanoma cells in vitro 36. This supports the hypothesis of 
using mAbs with in vivo rather than in vitro anti-tumor activity for the selection of 
mimotopes. 
To date, only one mimotope-based vaccine targeting the HMW-MAA has demonstrated 
anti-tumor activity in vitro 13 and in vivo 14. The identification of additional HMW-
MAA mimotopes as components of an effective polymimotope vaccine might depend 
on the in vivo anti-tumor activity of the selecting mAbs per se but also on the used 
animal model as well as on the paratope conformation of the mimotope-induced Abs. In 
addition, we suggest that the efficacy of every mimotope based vaccine should be 
evaluated in an animal model by active immunization. 
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Figures 
Fig. 1. Inhibition of mAb binding to HMW-MAA by synthetic peptides. Microtiter 
plates were coated with mAb TP61.5 and incubated with microsomal preparation of 
518A2 melanoma cells to catch HMW-MAA. Biotinylated mAbs were preincubated 
with increasing concentrations of generated peptide mimics, followed by incubation 
with HMW-MAA. (A) Biotinylated mAb VT80.12 was preincubated with synthetic 
peptide 15/3/6 ( ) and a control peptide ( ). (B) Biotinylated mAb VF1-TP43 was 
preincubated with synthetic peptide 43.12p3 ( ) as well as the control peptide ( ). 
Binding of biotinylated mAbs was measured using an AP-conjugated streptavidin. 
Percentage of inhibition was calculated as follows: 100 – (OD (inhibited)/OD 
(uninhibited) x 100). 
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Fig. 2. Antigen and HMW-MAA specific immune response of immunized rabbits. Left 
panel: Microtiter plates were coated with 15/3/6 coupled to BSA, KLH, or BSA and 
incubated with increasing concentrations of purified rabbit Abs from immunizations 
with 15/3/6-KLH or KLH to detect peptide and KLH specific Abs. Right panel: 
Microtiter plates were coated with mAb TP61.5 and incubated with microsomal 
preparations of the melanoma cell lines 518A2 or M14. Purified rabbit Abs were 
analyzed by administration of increasing Ab concentrations. 
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Fig. 3. HMW-MAA specific Ab response determined by FACS and IHC. (A) The 
human melanoma cell lines 518A2 and M14 were each incubated with 1 µg mAb 
VT80.12 (as positive control to detect HMW-MAA) or 100 µg purified rabbit Abs from 
immunizations with 15/3/6-KLH or KLH. Bound antibodies were detected with FITC-
labelled goat anti-mouse IgG or FITC-labelled goat anti-rabbit IgG. Histogram overlays 
show unstained (white) vs. stained cells (grey). (B) Immunohistochemistry on 518A2 
tumor tissues of C.B.17 SCID/SCID mice 14. HMW-MAA staining was done with PBS 
buffer (negative control), mAb VT80.12 (positive control), and biotinylated IgG 
fraction of either 15/3/6-KLH antiserum (anti-15/3/6) or KLH antiserum (anti-KLH). 
Bound Abs were detected with StrepAB/HRP and visualized by DAB-chromogen 
solution and subsequent hematoxylin counterstaining. 
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Fig. 4. Antigen specific immune response of immunized BALB/c mice. Serum samples 
from day 0 (preimmune serum; white bars), day 22 (grey bars), and day 41 (black bars) 
were tested in ELISA. Results are shown for each mouse individually. Peptide 
specificity of sera from mice immunized with 15/3/6-KLH or 43.12p3-KLH was 
assessed using the respective peptide-BSA conjugates. Sera from KLH immunized mice 
were tested for specificity of KLH. 
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Fig. 5. HMW-MAA specific immune response of immunized BALB/c mice. Human 
melanoma cell lines 518A2 and M14 were either incubated with 1 µg mAb VT80.12 (as 
positive control) or a 1:10 diluted serum pool of each group. Bound antibodies were 
detected with FITC-labelled goat anti-mouse IgG. Histogram overlays show unstained 
(white) and stained cells (grey). 
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Fig. 6. Inhibition of cell proliferation in vitro. [3H]Thymidine proliferation assay 
demonstrating the effects of the purified mouse Abs on HMW-MAA expressing 
melanoma cells. The 518A2 or M14 cells were incubated with increasing concentrations 
of purified Abs from the mouse immunizations with 15/3/6-KLH or KLH for 72 h and 
pulsed with [3H]thymidine. Data are shown in percentage of inhibition compared with 
untreated cells; cpm values of untreated cells were set at 100%. The values are the mean 
of three independent experiments. Percentage of inhibition was calculated as follows: 
100 – (OD (inhibited)/OD (uninhibited) x 100). 
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Concluding Remarks 
 
The aim of this thesis was the generation of a polymimotope vaccine against malignant 
melanoma. This vaccine should target several epitopes of the HMW-MAA, a tumor-
antigen which is highly expressed on human melanoma cells, using the mimotope 
approach to elicit a strong humoral anti-HMW-MAA immune response. The efficacy of 
this polymimotope vaccine should then be tested in a syngenic melanoma mouse model. 
The results obtained with this thesis should provide new know-how regarding the 
superior efficacy of multi- over mono-epitope targeting vaccines. 
 
Limitations regarding (1) the application of different panning strategies using phage 
display peptide libraries to identify mimotopes, (2) the presence of in vitro or in vivo 
biological activity of an antibody which is used for the identification of mimotopes, (3) 
the animal model used for immunization to obtain tumor antigen specific antibodies, 
and (4) the possible discrepancy between immunogenicity and antigenicity of 
mimotopes have been extensively discussed in chapter II and III. 
 
In addition to the already discussed limitations, there are three issues that need to be 
addressed. 
First, regarding phage display, the efficacy of selection can be enhanced to a certain 
extent by manipulating stringency which is the degree to which peptides with higher 
fitness are favored over peptides with lower fitness and is inversely proportional to yield 
which is the fraction of phage particles with a given fitness that survive selection [1,2]. 
Usually, peptides with high fitness should be isolated, but stringency can only be 
increased to a certain extent, as increasing stringency usually implicates decreased 
yield. Therefore, high yield of the fittest clones is of paramount importance in the first 
round of selection, whose input consists of all clones of a certain phage display peptide 
library [2]. Considering the facts that each clone is represented by only 100 phage 
particles on average and the yield for the fittest clones is sometimes not greater than 
1%, it is very likely that such clones are going to be lost during the first round of 
selection and can therefore never be recovered [2]. Clones that are obtained after the 
first round of selection can be amplified and are thus represented by millions of phages 
which can be applied in following rounds of selection. Thereafter, yield can be 
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decreased in favor of high stringency for the subsequent rounds. However, there is a 
limit to stringency, because in practice selection techniques are imperfect and there is an 
unavoidable background yield of all phages regardless of their fitness [2]. If stringency 
is set too high, the yield of a specifically selected phage will fall far below the 
background of a nonspecifically isolated phage, and all power of discrimination in favor 
of high fitness is lost [2]. 
 
Second, regarding the fact that a peptide which binds its selector antibody (thus 
qualifying it as an antigenic mimic) is not able to elicit antibodies directed against the 
target antigen when used to immunize naive animals (thus failing as an immunogenic 
mimic), there are additional considerations which should be mentioned [2]. 
Small peptides are often flexible and might adopt a certain conformation when binding 
the selector antibody but other conformations when eliciting new antibodies upon 
immunization [3,4]. Therefore, only few of these antibodies, if any, would cross-react 
with the authentic epitope. Furthermore, a peptide might be an antigenic mimic without 
being a true structural mimic. Such a peptide would bind the selector antibody in an 
entirely different way than does the original authentic epitope, via altogether different 
interactions [2]. 
However, the induction of mimotope specific antibodies is a much more difficult 
process and varies considerably from one mimotope to another. This may be reasonable 
since the immune system can differentiate different antigens and produces very different 
responses [5]. 
 
Third, as short synthetic peptides representing B cell epitopes, continuous/linear or 
discontinuous/conformational, are generally poor immunogens, they require conjugation 
to a carrier protein providing T helper cell epitopes and usually the co-administration of 
an adjuvant in order to induce an antibody response [6-8]. 
Because it is now difficult to obtain carriers such as tetanus toxoid (TT) or diphtheria 
toxoid, it seems to be a good and cheap alternative to use KLH, as it is a large (>2000 
kDa), highly glycosylated protein frequently used as a carrier protein in animals and 
humans due to its potent immunogenicity [9,10]. Nevertheless, there are epitopes on the 
surface of KLH that cross-react with a variety of different carbohydrate antigens [10]. 
May et al. immunized mice with mimotopes, which were identified for the 
glucuronoxylomannan (GXM) component of the capsular polysaccharide of 
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Cryptococcus neoformans, conjugated to KLH as carrier. They observed that KLH 
alone induced antibodies that cross-reacted with GXM, but did not confer protection 
against cryptococcal infection, suggesting that the cross-reactive epitope on KLH was 
not protective [10]. 
Additionally, different carriers may influence the immunogenicity of a mimotope 
conjugate. In this concern, Li et al. showed that antibodies induced upon immunization 
of mice with a CD20 mimotope coupled to KLH were capable of mediating more 
efficient complement killing of CD20+ cells when compared to the antibodies from mice 
vaccinated with the respective TT-conjugate [11]. Wondimu et al. observed the opposite 
when using GD2 ganglioside mimotopes coupled to KLH or synthesized as MAP 
(multiple-antigen peptides). Here, the KLH-conjugate was less efficient than the MAP 
[12]. 
In conclusion, the immunogenicity of a mimotope conjugate can be increased by using a 
correct carrier and caution needs to be taken when creating vaccines for carbohydrate 
antigens using KLH as carrier protein [10-12]. 
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